Ignite Creation Date:
2025-12-25 @ 2:13 AM
Ignite Modification Date:
2025-12-26 @ 6:56 PM
Study NCT ID:
NCT02611960
Status:
COMPLETED
Last Update Posted:
2023-07-13
First Post:
2015-11-19
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122/KEYNOTE-122)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-04-18
Start Date Type:
ACTUAL
Primary Completion Date:
2020-11-30
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-09-30
Completion Date Type:
ACTUAL
First Submit Date:
2015-11-19
First Submit QC Date:
None
Study First Post Date:
2015-11-23
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2021-11-16
Results First Submit QC Date:
None
Results First Post Date:
2021-12-15
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-06-26
Last Update Post Date:
2023-07-13
Last Update Post Date Type:
ACTUAL